Rare Disease Trial, Recruiting NCT05794217 Sponsor: Sanguine Biosciences Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT05794217
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 89 years old at the time you sign the consent form.
  • You weigh at least 110 pounds.
  • Your heart rate is between 50 and 110 beats per minute.
  • Your blood pressure falls within a specific healthy range (diastolic between 50–100 mmHg and systolic between 90–180 mmHg).
  • The medical team has determined that your veins are suitable for the blood collection procedure.
  • You have tested negative for Hepatitis B, Hepatitis C, and HIV within the last 30 days (unless the cell collection is specifically related to one of these conditions).
  • Your recent blood count results (taken within 30 days) fall within the ranges accepted by the trial site.
  • You are able to understand the study and are willing to sign a written consent form allowing your health information to be used.

Who may not be able to join:

  • You are younger than 18 or older than 89 years old.
  • You have a medical history that doctors determine makes the blood collection procedure unsafe for you.
  • You have received a blood transfusion within the last 30 days.
  • You have taken an unapproved (investigational) drug within the last 30 days.
  • You have severe or untreated heart, kidney, liver, or lung disease that would make the procedure unsafe.
  • You have a bleeding disorder.
  • You have a condition that causes long-term (chronic) anaemia.
  • You currently have an active infection affecting your whole body.
  • You take ACE inhibitor medications (a type of blood pressure drug) and are unable to safely stop taking them for 24 hours before the procedure.
  • You are pregnant.
  • You have donated a unit of blood within the last 2 months.
  • You are unable to understand the study well enough to sign the consent form yourself.
  • You need another person (a legal representative) to sign the consent form on your behalf.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sanguine Biosciences
Registry
ClinicalTrials.gov
Start date
28 September 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Leukopak

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov